N/A N=102 Increasing the Temporal Window in Individuals With Alcohol Use Disorder
Alcohol Use Disorder
Primary: Delay Discounting (DD) Rates (Studies 1 and 2) — -5.33; -6.03; -4.94; -5.79 ln(K-value)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Wired Magnetically Assisted Capsule Endoscopy and Esophageal Varices
Esophageal Varices
Primary: Aerosol-generating Amount — 8195; 0; 13296; 1483 Particles generated
Phase 2 N=16 Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
Phase 3 N=6 Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.
Spinal Cord Injury
Primary: Change in Trabecular Plate Width (Tb.PW) for Femur and Tibia at 4.5 Months — 1785.42; 1819.41; 1805.52; 1834.67 μm
N/A N=106 Evaluating an Analogy-Based Consultation Approach for Insulin-Treated Type 2 Diabetes Patients
Type 2 Diabetes
Primary: HbA1c — 10.31 Percentage (%) of HbA1c
Phase 3 N=783 Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Juvenile Idiopathic Arthritis
Primary: Composite of All Primary Endpoints — 13; 14; 41; 245 Participants — p=0.7357
N/A N=665 Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
Methamphetamine Abuse · Opioid-use Disorder · HIV Seropositivity
Primary: Increase in HIV Viral Suppression for HIV-positive Participants: High- vs. Low-Intensity Frontline Intervention With SMS in Stage 2 — 31; 35; 6; 3 Participants — p=0.447
Phase 2 N=10 Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Advanced Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8
Primary: Assessment of Tumor Response to Combination of Paricalcitol and Hydroxychloroquine With Common Front-line Therapy. — 43 percentage of participants
N/A N=407,869 ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action
Diabetes Mellitus
Primary: Social Risk Screening — 2.45; 2.16 Rate Ratio (RR)
Phase 3 N=180 Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Number of AEs, SAEs and AESIs — 3325; 107; 420 events
N/A N=46 Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
Colon Adenocarcinoma · Colorectal Carcinoma · Rectal Adenocarcinoma
Primary: Median Percentage of Text Messages That Participants Responded to That Asked for a Reply — 96 percentage of text messages
Phase 1 N=55 Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers
Pharmacokinetics
Primary: Pharmacokinetics Cmax Day 1 — 10.4; 22.7; 39.5; 45.2 ng/ml
N/A N=41,054 Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)
Hypertension
Primary: Blood Pressure Remeasurement — 245; 829; 1813 participants — p=<0.001
Phase 1 N=15 Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
HPV16 Associated Cervical Cancer
Primary: Safety and Feasibility as Assessed by Number of Participants With Treatment-related Adverse Events — 5; 3; 8; 7 Participants
N/A N=2,410 Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines
Acute Respiratory Failure · Shock
Primary: Mortality — 422; 443 Participants